Cannabis Use Disorder

Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s

AARHUS, Denmark — September 10, 2026 Teitur Trophics announced successful results from the Phase I clinical trial of TT-P34,...

By cGxPwire Editor
September 11, 2026

.Clinical

EPIK Biosciences Expands Ketamine and DXM Drug Portfolio

AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...

By cGxPwire Editor
September 11, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Cannabis Use Disorder

Teitur Trophics Advances TT-P34 Toward Phase II in Parkinson’s

EPIK Biosciences Expands Ketamine and DXM Drug Portfolio